CCXI:NSD-ChemoCentryx Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 25.06

Change

0.00 (0.00)%

Market Cap

USD 1.87B

Volume

2.48M

Avg Analyst Target

USD 51.33 (+104.84%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ChemoCentryx Inc (CCXI) Stock Analysis:
Based on the ChemoCentryx Inc stock forecasts from 6 analysts, the average analyst target price for ChemoCentryx Inc is USD 51.33 over the next 12 months. ChemoCentryx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ChemoCentryx Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, ChemoCentryx Inc’s stock price was USD 25.06. ChemoCentryx Inc’s stock price has changed by -7.44% over the past week, -12.66% over the past month and -61.09% over the last year.

About

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement ...Read More

Company Website : https://www.chemocentryx.com

Address : 835 Industrial Avenue, San Carlos, CA, United States, 94070

Employees : 133

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.77

52 Week High : 70.29

Short Ratio : 4.11

52 Week Low : 9.53

Shorted Shares : 5,681,114

200 Day Moving Average : 25.33

Shorted Shares Previous Month : 5,588,592

50 Day Moving Average : 36.26

Shares Held By Insiders : 17.70%

Short Percentage : 11.98%

Shares Held by Institutions : 64.86%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

 USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

 USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD57.99B 27.35 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD35.77B 4.66 5.67
BGNE BeiGene Ltd

N/A

 USD25.75B N/A N/A
SGEN Seagen Inc

N/A

 USD23.32B 55.02 44.86
GMAB Genmab A/S

N/A

 USD22.58B 51.93 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD16.81B 20.32 11.89

ETFs Containing CCXI

Symbol Name Weight Mer Price(Change) Market Cap
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

N/A

 USD0.03B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

N/A

 USD1.25B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.17% 17% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.17% 17% F 9% F
Trailing 12 Months  
Capital Gain -61.09% 42% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.09% 42% F 19% F
Trailing 5 Years  
Capital Gain 244.23% 87% B+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 244.23% 87% B+ 89% B+
Average Annual (5 Year Horizon)  
Capital Gain 113.78% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.78% 90% A- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 210.40% 11% F 6% F
Risk Adjusted Return 54.08% 84% B 74% C
Market Capitalization 1.87B 88% B+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.70 21% F 23% F
Price/Book Ratio 5.91 20% F 21% F
Price / Cash Flow Ratio -22.99 86% B 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -33.61% 74% C 29% F
Return on Invested Capital -20.65% 76% C 28% F
Return on Assets -15.11% 76% C 24% F
Debt to Equity Ratio 14.72% 46% F 64% D
Technical Ratios  
Short Ratio 4.11 42% F 28% F
Short Percent 11.98% 14% F 14% F
Beta 1.77 23% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.